Patient Guide: Ociperlimab and tislelizumab in advanced esophageal squamous cell carcinoma (AdvanTIG-203): a phase II study

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • ✓ Get matched to the right study location for you
  • ✓ Connect directly with study coordinators at 17 participating sites
  • ✓ Understand eligibility with our simplified screening tool
  • ✓ Free service - we're here to help you access clinical research
Trial ID: NCTNCT04732494
Status: COMPLETED_NEXT_PHASE_UPCOMING
Condition: advanced esophageal squamous cell carcinoma, recurrent/metastatic second-line ESCC
Phase: Phase II

Find a Study Location Near You

This study is available at 17 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • • Guangzhou,
  • • Taichung,
  • • Seoul,
  • • And 14 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily